Card image cap
AbbVie, Allergen to present 12 novel discoveries at AAD-2022

US biopharma firm AbbVie and Allergan Aesthetics, the maker of Botox, will jointly present 12 abstracts and two late-breaking presentations during the 2022 American Academy of Dermatology (AAD) annual meeting, in Boston. AbbVie said that the presentations would underline latest developments in their research including that on the efficacy,  durability and safety of RINVOQ (upadacitinib) and SKYRIZI (risankizumab-rzaa). Allergan aesthetics have revealed that the company will elaborate on its novel hydrating serum in addition to  hyaluronic acid (HA) injectable gel for jawline definition and onabotulinumtoxin A for the treatment of masseter muscle prominence.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment